Revefenacin
YUPELRI (revefenacin) is a prescription inhalation solution containing 175 mcg of revefenacin per 3 mL vial, used as an anticholinergic medication for respiratory conditions. Manufactured by Viatris Specialty LLC, it is administered via nebulizer for maintenance treatment. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | YUPELRI (revefenacin) is a prescription inhalation solution containing 175 mcg of revefenacin per 3 mL vial, used as an anticholinergic medication for respiratory conditions. Manufactured by Viatris Specialty LLC, it is administered via nebulizer for maintenance treatment. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Revefenacin",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Revefenacin — ANDA 210598 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210598"
}
]
|
| identifier | ANDA210598 |
| issued | 2016-09-16 |
| keyword |
[
"drug-information",
"drug-manufacturers",
"drug-safety",
"fda",
"health-care"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Revefenacin |
